文献速递消化、代谢与肾脏急症儿科与产科急症

混合闭环控制系统在1型糖尿病幼儿中的试验

Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes.
PubMed 文献 · N Engl J Med · 2023-01-01
一句话结论在2至6岁以下1型糖尿病患儿中,混合闭环胰岛素输注系统较标准治疗使血糖在目标范围内时间增加12.4个百分点(约每天3小时)。

这项为期13周的多中心试验以2:1比例随机分配至少2岁但不满6岁的1型糖尿病患儿,接受闭环系统或标准治疗(胰岛素泵或多日多次注射加持续葡萄糖监测)。共102例患儿入组,闭环组68例、标准治疗组34例,其中55例(81%)以虚拟方式启动闭环系统。闭环组血糖70至180 mg/dl目标范围内时间从基线56.7±18.0%升至13周随访期间的69.3±11.1%,标准治疗组从54.9±14.7%升至55.9±12.6%,平均校正差异12.4个百分点(约相当于每天3小时),95%CI 9.5至15.3,P<0.001。

要点

  • 2至6岁以下1型糖尿病患儿使用闭环系统13周后,目标血糖范围(70至180 mg/dl)时间达69.3±11.1%,标准治疗组为55.9±12.6%。
  • 闭环组较标准治疗组目标范围内时间平均校正差异12.4个百分点(约相当于每天3小时),95%CI 9.5至15.3,P<0.001。
  • 闭环系统在血糖高于250 mg/dl时间百分比、平均血糖和糖化血红蛋白水平上观察到相似的治疗效应(有利于闭环系统)。
  • 两组血糖低于70 mg/dl时间百分比无显著组间差异;闭环组发生2例严重低血糖、1例糖尿病酮症酸中毒,标准治疗组发生1例严重低血糖。
  • 102例患儿中55例(81%)以虚拟方式启动闭环系统。

适用人群与场景

  • 至少2岁但不满6岁、患有1型糖尿病的儿童;基线糖化血红蛋白水平范围为5.2%至11.5%。

处置流程与药物剂量

  • 闭环组接受闭环胰岛素输注系统治疗;标准治疗组接受胰岛素泵或多日多次注射胰岛素加持续葡萄糖监测。
  • 闭环系统启动在以虚拟方式进行于55例患者(81%)。

研究设计与关键结果

  • 研究类型为为期13周的多中心试验,按2:1比例随机分配;共102例患儿接受随机化,闭环组68例、标准治疗组34例。
  • 主要终点:闭环组血糖70至180 mg/dl目标范围内时间从基线56.7±18.0%增至13周随访期间的69.3±11.1%,标准治疗组从54.9±14.7%增至55.9±12.6%;平均校正差异12.4个百分点(约相当于每天3小时),95%CI 9.5至15.3,P<0.001。
  • 次要终点:血糖高于250 mg/dl时间百分比、平均血糖水平和糖化血红蛋白水平上观察到相似的治疗效应(有利于闭环系统);血糖低于70 mg/dl时间百分比无显著组间差异。
  • 安全性:闭环组发生2例严重低血糖、1例糖尿病酮症酸中毒;标准治疗组发生1例严重低血糖。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验;由美国国家糖尿病、消化和肾脏疾病研究所资助;PEDAP,ClinicalTrials.gov注册号NCT04796779。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在2至6岁以下1型糖尿病患儿中,闭环系统较标准治疗使血糖目标范围内时间增加12.4个百分点(约每天3小时),且未增加血糖低于70 mg/dl时间百分比。
  • 闭环组发生2例严重低血糖和1例糖尿病酮症酸中毒,标准治疗组发生1例严重低血糖。
  • 原文结论未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Closed-loop control systems of insulin delivery may improve glycemic outcomes in young children with type 1 diabetes. The efficacy and safety of initiating a closed-loop system virtually are unclear.

METHODS: In this 13-week, multicenter trial, we randomly assigned, in a 2:1 ratio, children who were at least 2 years of age but younger than 6 years of age who had type 1 diabetes to receive treatment with a closed-loop system of insulin delivery or standard care that included either an insulin pump or multiple daily injections of insulin plus a continuous glucose monitor. The primary outcome was the percentage of time that the glucose level was in the target range of 70 to 180 mg per deciliter, as measured by continuous glucose monitoring. Secondary outcomes included the percentage of time that the glucose level was above 250 mg per deciliter or below 70 mg per deciliter, the mean glucose level, the glycated hemoglobin level, and safety outcomes.

RESULTS: A total of 102 children underwent randomization (68 to the closed-loop group and 34 to the standard-care group); the glycated hemoglobin levels at baseline ranged from 5.2 to 11.5%. Initiation of the closed-loop system was virtual in 55 patients (81%). The mean (±SD) percentage of time that the glucose level was within the target range increased from 56.7±18.0% at baseline to 69.3±11.1% during the 13-week follow-up period in the closed-loop group and from 54.9±14.7% to 55.9±12.6% in the standard-care group (mean adjusted difference, 12.4 percentage points [equivalent to approximately 3 hours per day]; 95% confidence interval, 9.5 to 15.3; P<0.001). We observed similar treatment effects (favoring the closed-loop system) on the percentage of time that the glucose level was above 250 mg per deciliter, on the mean glucose level, and on the glycated hemoglobin level, with no significant between-group difference in the percentage of time that the glucose level was below 70 mg per deciliter. There were two cases of severe hypoglycemia in the closed-loop group and one case in the standard-care group. One case of diabetic ketoacidosis occurred in the closed-loop group.

CONCLUSIONS: In this trial involving young children with type 1 diabetes, the glucose level was in the target range for a greater percentage of time with a closed-loop system than with standard care. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases; PEDAP ClinicalTrials.gov number, NCT04796779.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Wadwa RP, Reed ZW, Buckingham BA, et al. Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes. N Engl J Med. 2023. PMID: 36920756. doi:10.1056/NEJMoa2210834

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。